Lapatinib: A sword with two edges

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalPathology and Oncology Research
Volume14
Issue number1
DOIs
Publication statusPublished - Mar 2008

Fingerprint

Protein-Tyrosine Kinases
Diarrhea
Clinical Trials
Breast Neoplasms
Neoplasm Metastasis
Skin
lapatinib
Brain
Neoplasms
Trastuzumab
Capecitabine
Cardiotoxicity

Keywords

  • Breast cancer
  • EGFR-inhibition
  • HER2-inhibition
  • Lapatinib
  • Targeted therapy
  • Trastuzumab resistency

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pathology and Forensic Medicine

Cite this

Lapatinib : A sword with two edges. / Kópper, L.

In: Pathology and Oncology Research, Vol. 14, No. 1, 03.2008, p. 1-8.

Research output: Contribution to journalArticle

@article{f80e1ff1a6ea46c4b8cc87486776edda,
title = "Lapatinib: A sword with two edges",
abstract = "Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.",
keywords = "Breast cancer, EGFR-inhibition, HER2-inhibition, Lapatinib, Targeted therapy, Trastuzumab resistency",
author = "L. K{\'o}pper",
year = "2008",
month = "3",
doi = "10.1007/s12253-008-9018-z",
language = "English",
volume = "14",
pages = "1--8",
journal = "Pathology and Oncology Research",
issn = "1219-4956",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Lapatinib

T2 - A sword with two edges

AU - Kópper, L.

PY - 2008/3

Y1 - 2008/3

N2 - Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.

AB - Lapatinib is an oral dual tyrosine kinase inhibitor targeting EGFR1 and EGFR2 (HER2). Phase I trials have shown that lapatinib is well tolerated, with mild diarrhea and skin rush as common adverse effects, and low cardiotoxicity. Phase II and III trials provided evidences on clinical effectiveness in advanced or metastatic breast cancer and potential against brain metastases. Lapatinib is active in combination with trastuzumab and in trastuzumab-resistant patients, moreover it has synergistic action with capecitabine. Several clinical trials are in progress to explore the effectiveness of lapatinib in other combinations and against several tumor types.

KW - Breast cancer

KW - EGFR-inhibition

KW - HER2-inhibition

KW - Lapatinib

KW - Targeted therapy

KW - Trastuzumab resistency

UR - http://www.scopus.com/inward/record.url?scp=41949125812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41949125812&partnerID=8YFLogxK

U2 - 10.1007/s12253-008-9018-z

DO - 10.1007/s12253-008-9018-z

M3 - Article

C2 - 18409020

AN - SCOPUS:41949125812

VL - 14

SP - 1

EP - 8

JO - Pathology and Oncology Research

JF - Pathology and Oncology Research

SN - 1219-4956

IS - 1

ER -